分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Carrier free nanomedicine for synergistic cancer therapy by initiating apoptosis and paraptosis

Rongrong Zheng, Yibin Liu, Baixue Yu, Linping Zhao, Ni Yang, Ali Chen, Lin Xu, Hong Cheng, Xueyan Jiang, Shiying Li

Journal:JOURNAL OF COLLOID AND INTERFACE SCIENCE

IF:9.97

DOI:10.1016/j.jcis.2022.04.090

PMID:35512593

Published:2022-04-20

research field:线粒体生物学肺科学新生儿学分子医学

Abstract

Although photodynamic therapy (PDT) has been well-known as a promising anti-tumor treatment, its limited therapeutic efficiency remains to be a large challenge. In this study, a carrier free nanomedicine (designated as PyroMor) is developed to greatly initiate cell apoptosis and paraptosis for synergistic cancer therapy. Pyropheophorbide-a (Pyro) and morusin (Mor) are capable of self-assembling into PyroMor, which has been testified to have superiority of improved stability, cellular internalization, and biocompatibility. Because of efficient cellular uptake behavior, PyroMor could induce cellular paraptosis by Mor-caused vacuolation in mitochondria , ER and cytoplasm, contributing to improving the PDT efficacy of Pyro. Therefore, self-delivery PyroMor is able to accomplish synergistic anti-tumor effect via stimulation of cell apoptosis as well as paraptosis. In addition, in vivo studies also clarify that PyroMor presents passive tumor targeting delivery, leading to robust repressive effect on tumor proliferation with negligible systemic toxicity. This strategy of combined cancer therapy by initiating both cell apoptosis and paraptosis extremely benefits to the development of precise and effective cancer therapy in clinic.

本文使用的Yeasen产品

购物车
客服
转染试用